Jayex Healthcare Limited develops healthcare industry service technologies and integrated dispensing automation systems for the pharmaceutical and healthcare sectors in Australia and the United Kingdom.
+ 1 more risk
Overvalued with worrying balance sheet.
Share Price & News
How has Jayex Healthcare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: JHL's share price has been volatile over the past 3 months.
7 Day Return
AU Healthcare Services
1 Year Return
AU Healthcare Services
Return vs Industry: JHL underperformed the Australian Healthcare Services industry which returned 27.7% over the past year.
Return vs Market: JHL underperformed the Australian Market which returned -19.1% over the past year.
Price Volatility Vs. Market
How volatile is Jayex Healthcare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHow Much Of Jayex Healthcare Limited (ASX:JHL) Do Insiders Own?
1 month ago | Simply Wall StIs Jayex Healthcare Limited's (ASX:JHL) CEO Pay Fair?
2 months ago | Simply Wall StIs Jayex Healthcare (ASX:JHL) Using Debt In A Risky Way?
Is Jayex Healthcare undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate JHL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate JHL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: JHL is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.
PE vs Market: JHL is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate JHL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: JHL is good value based on its PB Ratio (0.5x) compared to the AU Healthcare Services industry average (2.7x).
How is Jayex Healthcare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jayex Healthcare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of JHL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Jayex Healthcare competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Jayex Healthcare performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: JHL is currently unprofitable.
Growing Profit Margin: JHL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: JHL is unprofitable, but has reduced losses over the past 5 years at a rate of 24.5% per year.
Accelerating Growth: Unable to compare JHL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JHL is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (12.8%).
Return on Equity
High ROE: JHL has a negative Return on Equity (-23.07%), as it is currently unprofitable.
How is Jayex Healthcare's financial position?
Financial Position Analysis
Short Term Liabilities: JHL's short term assets (A$2.9M) do not cover its short term liabilities (A$5.1M).
Long Term Liabilities: JHL's short term assets (A$2.9M) do not cover its long term liabilities (A$4.3M).
Debt to Equity History and Analysis
Debt Level: JHL's debt to equity ratio (104.2%) is considered high.
Reducing Debt: JHL had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: JHL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: JHL has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.9% each year.
What is Jayex Healthcare's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate JHL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate JHL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if JHL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if JHL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of JHL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Nick Fernando has been the Chief Executive Officer of Jayex Healthcare Limited since May 23, 2017. Mr. Fernando has been Managing Director at Jayex Technology Limited at Jayex Healthcare Limited since ...
CEO Compensation Analysis
Compensation vs Market: Nick's total compensation ($USD262.12K) is about average for companies of similar size in the Australian market ($USD238.47K).
Compensation vs Earnings: Nick's compensation has increased whilst the company is unprofitable.
|Executive Chairman||no data||AU$60.00k||no data|
|Chief Executive Officer||2.92yrs||AU$436.20k||no data|
|Chief Financial Officer||1.67yrs||AU$146.87k||no data|
|Company Secretary||4.67yrs||no data||no data|
Experienced Management: JHL's management team is considered experienced (2.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Jayex Healthcare Limited's company bio, employee growth, exchange listings and data sources
- Name: Jayex Healthcare Limited
- Ticker: JHL
- Exchange: ASX
- Founded: 2006
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$2.645m
- Shares outstanding: 176.36m
- Website: https://www.jayex.com/en-au/
Number of Employees
- Jayex Healthcare Limited
- 17B Cribb Street
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|JHL||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Dec 2015|
|JHL||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Dec 2015|
Jayex Healthcare Limited develops healthcare industry service technologies and integrated dispensing automation systems for the pharmaceutical and healthcare sectors in Australia and the United Kingdom. The company offers Jayex Connect platform, a cloud-based patient engagement platform, which provides appointment booking, patient calling, patient check-in, health messaging, and script management solutions. Jayex Healthcare Limited was founded in 2006 and is based in Milton, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/06 10:51|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.